#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Modern trends in local treatment of diabetic foot


Authors: Emil Martinka
Authors‘ workplace: Národný endokrinologický a diabetologický ústav, n. o., Ľubochňa
Published in: Forum Diab 2019; 8(2): 88-97
Category: Review Article

Overview

Diabetic foot (DF) is a frequent and medically serious complication of diabetes mellitus (DM) with significant socio-economic impact as well as impact on patient’s quality of life. It is the most common (85%) cause of lower limb amputation and is associated with increased mortality which is comparable with cancer. This highlights the need to address this issue and seek new treatment options. According to data from the National Center of Health Information (NCZI), there were 8,596 (prevalence of 2.4%) of diabetic patients with DF with lesion and 4,196 (prevalence of 1,19%) of patients with a history of DF-amputation registered in Slovakia in 2017. The annual incidence of DF with a lesion was 1,325 new cases (3.74 /1,000 patients per year/PPY) and an incidence of amputations was 413 cases (1.17/1,000 PPY). Thus, the incidence and prevalence of DF and amputations for DF in Slovakia are comparable, or lower than the most commonly reported average in European countries or the US literature. However, direct comparison of these data is limited. The characteristic medical problem of DF is the complexity of pathophysiology, and, due to functional and physical changes induced by diabetes and the deploying processes, failure of repair process, transition to chronicity, non-responsiveness to local treatment, increased bacterial load by pathogenic biofilm, deficiency of growth factors, increased content and degradation by proteases, accelerated cell aging, chronic inflammatory organism and others. During wound healing, ulceration passes through several phases, which can be divided into a purification phase/infection elimination, granulation phase and epithelialization phase. The basis of the treatment of diabetic ulcerations is local leg relief, regular mechanical or enzymolytic debridement, treatment of infection, treatment of ischemia, relief, moist dressing. If basic care is not enough, other options include vacuum therapy, topical application of growth factors, hyperbaric oxygen therapy, and other methods that we have dealt with in other publications. Procedures that have recently been included in our therapeutic armamentaria include treatment with air plasma and exogenous nitric oxide (NO), using Plason, promoting binding epithelialization by applying the Amnioderm lyophilized human amniotic membrane-based biological healing membrane and topical cream based on goat colostrum containing lactoferrin and other biologically active ingredients.

Keywords:

diabetic foot – Nitric oxide – Plason – Amnioderm – goat colostrum


Sources
  1. Acosta JB, Savigne W, Valdez C et al. Epidermal growth factor intralesional infi ltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J 2006; 3(3): 232–339. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1742–481X.2006.00237.x>.
  2. Akle CA, Adinolfi M, Welsh KI et al. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet 1981; 2(8254): 1003–1005.
  3. Armstrong DG, Wrobel J, Robbins JM. Guest Editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 2007; 4(4): 286–287. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1742–481X.2007.00392.x>.
  4. Berlanga-Acosta J, Fernández-Montequín J, Valdés-Pérez Cet al. Diabetic Foot Ulcers and Epidermal Growth Factor: Revisiting the Local Delivery Route for a Successful Outcome. Biomed Res Int 2017; 2017: 2923759. Dostupné z DOI: <http://dx.doi.org/10.1155/2017/2923759>.
  5. Boulton AJM. The diabetic foot. Medicine 2015; 43(1): 33–37. Dostupné z DOI: <https: //doi.org/10.1016/j.mpmed.2014.10.006>.
  6. Borssén B, Bergenheim T, Lithner F. The epidemiology of foot lesions in diabetic patients aged 15–50 years. Diabet Med 1990; 7(5): 438–444.
  7. Capramedic. Dostupné z WWW: <http://www.dermatology.sk/capramedic.php>.
  8. Cornwell KG, Landsman A, James KS. Extracellular matrix biomaterials for soft tissue repair. Clin Podiatr Med Surg 2009; 26(4): 507–23. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cpm.2009.08.001>.
  9. Dinh T, Elder S. Delayed wound healing in diabetes: considering future treatments Diabetes Manage 2011; 1(5): 509–519. Dostupné z DOI: <http://dx.doi.org/10.2217/DMT.11.44>.
  10. Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in advanced diabetic foot ulcer: Treatment up to complete wound closure. Int Wound J 2009; 6(1): 67–72. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1742–481X.2008.00561.x>.
  11. Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG et al. Intralesional injections of recombinant human Epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers. Multicenter, randomized, placebo-controlled, double blind study. Int Wound J 2009; 6(6): 432–443. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1742–481X.2009.00641.x>.
  12. Fisman EZ, Adler Y, Tenenbaum A. Biomarkers in cardiovascular diabetology: interleukins and matrixins. Adv Cardiol 2008; 45: 44–64. Dostupné z DOI: <http://dx.doi.org/10.1159/0000115187>.
  13. Gibbons G, Eliopoulos GM. Infection of the diabetic foot. In: Kozak GP et al (eds). Management of Diabetic Foot Problems. Saunders: Philadelphia, PA, USA 1984. ISBN 13: 978–0721612843.
  14. Guaragna MA, Albanesi M, Stefani S et al. The effectiveness of oral goat colostrum in the treatment of patients with type 2 diabetes mellitus: our preliminary experience. Clin Ter 2013; 164(2): 111–114. Dostupné z DOI: <http://dx.doi.org/10.7417/CT.2013.1527>.
  15. Hao Y1, Ma DH, Hwang DG et al. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea 2000; 19(3): 348–352.
  16. Hatanaka E, Monteagudo PT, Marrocos MS et al. Neutrophils and monocytes as potentially important sources of proinflammatory cytokines in diabetes. Clin. Exp. Immunol 2006; 146(3): 443–447. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2249.2006.03229.x>.
  17. Heckmann N, Auran R, Mirzayan R1. Application of Amniotic Tissue in Orthopedic Surgery. Am J Orthop (Belle Mead NJ) 2016; 45(7): E421-E425.
  18. Holman H, Young RJ, Jeffcoate WJ: Variation in the recorded incidence of amputation of the lower limb in England. Diabetologia 2012; 55(7): 1919–1925. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–012–2468–6>.
  19. Holmes C, Wrobel JS, Maceachern MP et al. Collagen-based wound dressings for the treatment of diabetes-related foot ulcers: a systematic review. Diabetes Metab Syndr Obes 2013; 6: 17–29. Dostupné z DOI: <http://dx.doi.org/10.2147/DMSO.S36024>.
  20. Chesnokova NB, Gundorova RA, Kvasha OI et al. An experimental substantiation of nitric-oxide containing gas flow in the treatment of eye traumas. Vestn Ross Akad Med Nauk 2003; (5): 40–44.
  21. Jeyaraman K, Berhane T, Hamilton M et al. Mortality in patients with diabetic foot ulcer: a retrospective study of 513 cases from a single Centre in the Northern Territory of Australia. BMC Endocr Disord. 2019; 19(1): 1. Dostupné z DOI: <http://dx.doi.org/10.1186/s12902–018–0327–2>.
  22. Jneid J1, Cassir N1, Schuldiner S et al.Dostupné z DOI: Exploring the Microbiota of Diabetic Foot Infections With Culturomics Front Cell Infect Microbiol 2018; 8: 282. Dostupné z DOI: <http://dx.doi.org/10.3389/fcimb.2018.00282>.
  23. Johannesson A1, Larsson GU, Ramstrand N et al. Incidence of lower-limb amputation in the diabetic and nondiabetic general population: a 10-year population-based cohort study of initial unilateral and contralateral amputations and reamputations. Diabetes Care 2009; 32(2): 275–280. Dostupné z DOI: <http://dx.doi.org/10.2337/dc08–1639>.
  24. Jupiter DC, Thorud JC, Buckley CJ et al. The impact of foot ulceration and amputation on mortality in diabetic patients. I: From ulceration to death, a systematic review. Int Wound J 2016; 13(5): 892–903. Dostupné z DOI: <http://dx.doi.org/10.1111/iwj.12404>.
  25. Kavitha KV, Tiwari S, Purandare VB et al. Choice of wound care in diabetic foot ulcer: A practical approach. World J Diabetes 2014; 5(4): 546–556. Dostupné z DOI: <http://dx.doi.org/10.4239/wjd.v5.i4.546>.
  26. Keck CW. The United States and Cuba — Turning Enemies into Partners for Health. N Engl J Med 2016; 375(16): 1507–1509. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMp1608859>.
  27. Kim JS, Kim JC, Na BK et al. Amniotic membrane patching promotes healing and inhibits proteinase activity on wound healing following acute corneal alkali burn. Exp Eye Res 2000; 70(3): 329–337. Dostupné z DOI: <http://dx.doi.org/10.1006/exer.1999.0794>.
  28. King AE, Paltoo A, Kelly RW et al. Expression of natural antimicrobials by human placenta and fetal membranes. Placenta 2007; 28(2–3): 161–169. Dostupné z DOI: <http://dx.doi.org/10.1016/j.placenta.2006.01.006>.
  29. Khrupkin VI, Zudilin AV, Pisarenko LV et al. Local application of low-energy aerial and argon plasma in the treatment of suppurative wounds and trophic ulcers. Vestn Khir Im I I Grek 2001; 160(2): 39–45.
  30. Khrupkin VI, Pisarenko LV, Slostin SM et al. Use of physical plasma in surgery of wounds and wound complications. Vestn Khir Im I I Grek 1998; 157(2): 43–47.
  31. Kshirsagar AY, Vekariya MA, Gupta V et al. A comparative study of colostrum dressing versus conventional dressing in deep wounds. J Clin Diagn Res 2015; 9(4): PC01-PC04. Dostupné z DOI: <http://dx.doi.org/10.7860/JCDR/2015/12004.5739>.
  32. Kumar S, Ashe HA, Parnell LN et al. The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. Diabet Med 1994; 11(5): 480–484.
  33. Lazarus GS, Cooper DM, Knighton DR et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch. Dermatol 1994; 130(4): 489–493.
  34. López-Valladares MJ, Rodríguez-Ares TM, Touriño R et al. Donor age and gestational age influence on growth factor levels in human amniotic membrane. Acta Ophthalmol 2010; 88(6): e211–216. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1755–3768.2010.01908.x>.
  35. Manes C, Papazoglou N, Sossidou Eet al. Prevalence of diabetic neuropathy and foot ulceration: identification of potential risk factors—a population-based study. Wounds 2002; 14(1): 11–15.
  36. Marme I, Pottier N, Sainthillier JM et al. Use of amniotic membrane transplantation in the treatment of venous leg ulcers. Wound Repair Regen 2007; 15(4): 459–464. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1524–475X.2007.00252.x>.
  37. Martinka E, Tkáč I, Mokáň M (eds). Interdisciplinárne štandardy diagnostiky a liečby diabetes mellitus, jeho komplikácií a najvýznamnejších sprievodných ochorení. Forum Diab 2018; 7(2; Suppl 1): 5–153.
  38. Moghazy AM, Abbas AH. Assessment of amniotic and polyurethane membrane dressings in the treatment of burns. Burns 2010; 36: 703–710. Dostupné z DOI: <10.1016/j.burns.2009.09.003>.
  39. Moxey W, Gogalniceanu P, Hinchliffe RJ et al. Lower extremity amputations – a review of global variability in incidence. Diabet Med 2011; 28(10): 1144–1153. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2011.03279.x>.
  40. Napoli C, Paolisso G, Casamassimi A et al. Effects of Nitric Oxide on Cell Proliferation: Novel Insights. J Am Coll Cardiol 2013; 62(2): 89–95. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.03.070>.
  41. NCZI. Dostupné z WWW: Dostupné z DOI: <http://www.nczisk.sk/Documents/publikacie/2017/zs1811.pdf>.
  42. Niknejad H, Peirovi H, Jorjani M et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater 2008; 15: 88–99.
  43. Ono I, Gunji H, Zhang JZ et al. Studies on cytokines related to wound healing in donor site wound fluid. J Dermatol Sci 1995; 10(3): 241–245. Dostupné z DOI: <http://dx.doi.org/10.1016/0923–1811(95)00454-Z>.
  44. Paisey RB, Abbott A, Levenson R, et al. and the South‐West Cardiovascular Strategic Clinical Network peer diabetic foot service review team Diabetes‐related major lower limb amputation incidence is strongly related to diabetic foot service provision and improves with enhancement of services: peer review of the South‐West of England. Diabet Med 2018; 35(1): 53–62. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.13512>.
  45. Panigrahi AK, Sahoo MK, Mohapatra S et al. Role of Bovine Colostrum in Healing of Chronic Non-Healing Ulcers – A Clinical Study. J Med Sci Clin Res 2018; 6(11): 2014–2017. Dostupné z DOI: <https: //dx.doi.org/10.18535/jmscr/v6i11.37>.
  46. Park YJ, Hwang Y, Park KH: Collagen Dressing in the Treatment of Diabetic Foot Ulcer: A Prospective, Randomized, Placebo-Controlled, Single-Center Study. J Foot Ankle 2016. Dostupné z DOI: <https: //doi.org/10.1177/2473011416S00080>.
  47. Parolini O, Solomon A , Evangelista M et al. Human term placenta as a therapeutic agent: from the first clinical applications to future perspectives. In: Berven E, Freberg A (eds). Human placenta: structure and development, Circulation and Functions (Pregnancy and Infants: Medical, Psychological and Social Issues). Nova Science: Hauppauge, New York: 2010: 1–48. ISBN 978–160876457.
  48. Plason. Dostupné z WWW: <http://www.biorelax.sk/?l1=plason>.
  49. Rachman AB, Maheswari RRA, Bachroem MS. Composition and Isolation of Lactoferrin from Colostrum and Milk of Various Goat Breeds. Procedia Food Sci 2015; 3: 200–210. Dostupné z DOI: <http://dx.doi.org/10.1016/j.profoo.2015.01.022>.
  50. Reiber GE. The epidemiology of foot ulcers and amputations in the diabetic foot. In: Bowker JH, Pfeiter MA (eds). Levin and o’Neal’s The Diabetic Foot. 6th ed. Mosby: St Louis 2001: 13–32. ISBN 978–1556644719.
  51. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg 1998, 176(2A Suppl): S5–S10.
  52. Reiber GE, Vileikyte L, Boyko EJ et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22(1): 157–162.
  53. Shaw JE, Boulton AJ. The pathogenesis of diabetic foot problems: an overview. Diabetes 1997; 46(Suppl 2): S58–S61.
  54. Schairer DO, Chouake JS, Nosanchuk JD, Friedman AJ. The potential of nitric oxide releasing therapies as antimicrobial agents. Virulence 2012; 3(3): 271–279. Dostupné z DOI: <http://dx.doi.org/10.4161/viru.20328>.
  55. Shekhter AB, Serezhenkov VA, Rudenko TG et al: Beneficial effect of gaseous nitric oxide on the healing of skin wounds.Nitric oxide 2005; 12(4): 210–219. Dostupné z DOI: <http://dx.doi.org/10.1016/j.niox.2005.03.004>.
  56. Talmi Y, Sigler U, Inge E et al. Antibacterial properties of human amniotic membranes. Placenta 1991; 12(3): 285–288.
  57. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor‐beta isoforms, TGF‐beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol 1999; 179(3): 325–335. Dostupné z DOI: <http://dx.doi.org/10.1002/(SICI)1097–4652(199906)179:3<325::AID-JCP10>3.0.CO;2-X>.
  58. Uruakpa FO, Ismond MAH, Akobundu EN. Colostrum and its benefits: A review. Nutr Res 2002; 22(6): 755–767. Dostupné z DOI: <https://doi.org/10.1016/S0271–5317(02)00373–1>.
  59. Valenzuela-Silva CM, Tuero-Iglesias ÁD, García-Iglesias Eet al. Granulation Response and Partial Wound Closure predict Healing in Clinical Trials on Advanced Diabetes Foot Ulcers Treated with Recombinant, Human Epidermal Growth Factor. Diabetes Care 2013; 36(2): 210–215. Dostupné z DOI: <http://dx.doi.org/10.2337/dc12–1323>.
  60. Yera-Alos IB, Alonso-Carbonell L, Valenzuela-Silva CM et al. Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers. BMC Pharmacol Toxicol 2013; 14: 44. Dostupné z DOI: <http://dx.doi.org/10.1186/2050–6511–14–44>.
  61. Yorkshire and Humber Public Health Observatory YHPHO. Diabetes footcare activity profiles. Diabetes Health Intelligence 2016. Dostupné z WWW: <https//www.gov.uk/guidance/phe>.
  62. López-Saura PA, Yera-Alos IB, Valenzuela-Silva C et al. Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic Foot Ulcers. Adv Pharmacoepidem Drug Safety 2013; 2(2): 128. Dostupné z DOI: <http://doi:10.4172/2167–1052.1000128>.
  63. Reber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus. A case – control study. Ann Intern Med 1992; 117(2): 97–105.
  64. Berlanga-Acosta J, Gavilondo-Cowley J, García del Barco-Herrera D et al. Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as tissue healing agents: clarifying concerns about their possible role in malignant transformation and tumor progression. J Carcinogene Mutagene 2011; 2: 115. Dostupné z DOI: <http://doi: 10.4172/2157–2518.1000115>.
  65. Martinka E. Kardiovaskulárna morbidita a mortalita pacientov s diabetes mellitus 2. typu na Slovensku. Výsledky štúdie NEFRITI II. Edukačný portál SDiA 2019. Dostupné z WWW: <http://lekar.sdia.sk/sdia-lekarske-profesne-zdruzenie-aktuality/170/kardiovaskularna-morbidita-a-mortalita-pacientov-s-diabetes-mellitus-2-typu-na-slovensku-vysledky-studie-nefriti-ii/>.
  66. Bashir O, Fitzgerald AJ, Berlanga-Acosta J. Effect of epidermal growth factor administration on intestinal cell proliferation, crypt fission and polyp formation in multiple intestinal neoplasia (Min) mice. Clin Sci (Lond) 2003; 105(3): 323–330. Dostupné z DOI: <http://doi: 10.1042/CS20030023>.
  67. Knowles AF, Salas Prato M, Villela J. Epidermal growth factor inhibits growth while increasing the expression of an ecto-calcium-ATPase of a human hepatoma cell line. Biochem Biophys Res Commun 1985; 126(1): 8–14.
  68. Barnes DW. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free culture. J Cell Biol 1982; 93(1): 1–4. Dostupné z DOI: <http://doi: 10.1083/jcb.93.1.1>.
Labels
Diabetology Endocrinology Internal medicine

Article was published in

Forum Diabetologicum

Issue 2

2019 Issue 2

Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#